Gowling WLG advises on partnership to treat neurological disorders
In April 2016, Gowling WLG advised Heptares, a wholly-owned subsidiary of Sosei Group Corporation, on a $3.375bn global R&D and commercialisation partnership with Allergan to license a broad portfolio of compounds targeting neurological disorders, including Alzheimer’s disease. The collaboration is a step towards advancing the development of and commercialisation of treatments which could help the […]